<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04859764</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300006118</org_study_id>
    <nct_id>NCT04859764</nct_id>
  </id_info>
  <brief_title>Effect of Reparel Knee Sleeve With Knee Injection</brief_title>
  <official_title>Effects of Corticosteroid Injection Plus Reparel™ Knee Sleeve on Knee Osteoarthritis: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Reparel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goals of treating knee osteoarthritis (OA) is to improve or maintain quality of life,&#xD;
      mobility and function, pain relief, and improve inflammation. The different treatment options&#xD;
      for knee OA have been extensively studied and implemented, but the optimum treatment is still&#xD;
      undecided. There is a belief that anti-inflammatory sleeve technology may be beneficial in&#xD;
      treating knee OA. The purpose of this study is to determine if the Reparel™ knee sleeve&#xD;
      results in superior mobility, functionality, and pain outcomes as compared to a placebo knee&#xD;
      sleeve in managing knee OA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who are recommended non-operative management of their knee osteoarthritis and have&#xD;
      consented to participate in the study will be randomized into two groups to receive either of&#xD;
      the following&#xD;
&#xD;
        1. Reparel knee sleeve&#xD;
&#xD;
        2. Placebo knee sleeve&#xD;
&#xD;
      Participants assigned to both groups will be given instructions on how to use/wear the sleeve&#xD;
      while performing activities of daily living or sports that had previously resulted in knee&#xD;
      pain and also be asked to do the follows:&#xD;
&#xD;
        -  Wear the sleeve as much as they possibly can&#xD;
&#xD;
        -  Not change their usual activities and diet during the time they are on this study.&#xD;
&#xD;
        -  Record in a diary the number of hours sleeve was worn per day&#xD;
&#xD;
        -  Record any adverse effects or discomfort due to sleeve use.&#xD;
&#xD;
        -  Not to receive any injections in the subsequent 6 months following baseline&#xD;
           randomization visit.&#xD;
&#xD;
      Participant background information that is relevant to this study will also be collected from&#xD;
      their medical record including age, sex, and race and stored in a hospital secure computer&#xD;
      database (REDCap).&#xD;
&#xD;
      Participants will also be asked to complete the Knee Injury and Osteoarthritis Outcome Score&#xD;
      (KOOS), Single Assessment Numeric Evaluation (SANE), Oxford Knee Score (OKS), Lysholm Score,&#xD;
      UCLA Activity Score and Visual Analog Scale (VAS) survey questionnaires at baseline&#xD;
      randomization visit (T0), at 4 weeks (T1), at 3 months (T2), and at 6 months (T3) to assess&#xD;
      the mobility, functionality, and pain associated with the affected leg.&#xD;
&#xD;
      The responses to the surveys will be recorded on a password-protected laptop and all patient&#xD;
      identifiers will be replaced with unique identifier numbers. Only the study team will have&#xD;
      access to the responses from the forms. The analysis of de-identified data will be done&#xD;
      through SPSS 27, and scores for the questionnaires will be averaged and compared between the&#xD;
      two groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Unmarked sleeves will be used. Half will be Reparel sleeves, and half will be placebo. Participants and sleeve numbers will be randomized via REDCap.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in University of California, Los Angeles (UCLA) Activity Score at 4 weeks</measure>
    <time_frame>4 weeks (T1)</time_frame>
    <description>activity score, 1-10, 10 is best outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in University of California, Los Angeles (UCLA) Activity Score at 3 months</measure>
    <time_frame>3 months (T2)</time_frame>
    <description>activity score, 1-10, 10 is best outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in University of California, Los Angeles (UCLA) Activity Score at 6 months</measure>
    <time_frame>6 months (T3)</time_frame>
    <description>activity score, 1-10, 10 is best outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Lysholm Score at 4 weeks</measure>
    <time_frame>4 weeks (T1)</time_frame>
    <description>ability to manage activities of daily living, 0-100, 100 is best outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Lysholm Score at 3 months</measure>
    <time_frame>3 months (T2)</time_frame>
    <description>ability to manage activities of daily living, 0-100, 100 is best outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Lysholm Score at 6 months</measure>
    <time_frame>6 months (T3)</time_frame>
    <description>ability to manage activities of daily living, 0-100, 100 is best outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Oxford Knee Score (OKS) at 4 weeks</measure>
    <time_frame>4 weeks (T1)</time_frame>
    <description>knee pain and function score, 0-48, 48 is best outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Oxford Knee Score (OKS) at 3 months</measure>
    <time_frame>3 months (T2)</time_frame>
    <description>knee pain and function score, 0-48, 48 is best outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Oxford Knee Score (OKS) at 6 months</measure>
    <time_frame>6 months (T3)</time_frame>
    <description>knee pain and function score, 0-48, 48 is best outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) at 4 weeks</measure>
    <time_frame>4 weeks (T1)</time_frame>
    <description>knee pain and function score, 0-100, 100 is best outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) at 3 months</measure>
    <time_frame>3 months (T2)</time_frame>
    <description>knee pain and function score, 0-100, 100 is best outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) at 6 months</measure>
    <time_frame>6 months (T3)</time_frame>
    <description>knee pain and function score, 0-100, 100 is best outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Single Assessment Numeric Evaluation (SANE) at 4 weeks</measure>
    <time_frame>4 weeks (T1)</time_frame>
    <description>function score, 0-100%, 100% is best outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Single Assessment Numeric Evaluation (SANE) at 3 months</measure>
    <time_frame>3 months (T2)</time_frame>
    <description>function score, 0-100%, 100% is best outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Single Assessment Numeric Evaluation (SANE) at 6 months</measure>
    <time_frame>6 months (T3)</time_frame>
    <description>function score, 0-100%, 100% is best outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Visual Analog Scale (VAS) at 4 weeks</measure>
    <time_frame>4 weeks (T1)</time_frame>
    <description>pain score, 0-10, 10 is best outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Visual Analog Scale (VAS) at 3 months</measure>
    <time_frame>3 months (T2)</time_frame>
    <description>pain score, 0-10, 10 is best outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Visual Analog Scale (VAS) at 6 months</measure>
    <time_frame>6 months (T3)</time_frame>
    <description>pain score, 0-10, 10 is best outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with knee sleeve at 4 weeks</measure>
    <time_frame>4 weeks (T1)</time_frame>
    <description>0-10, 10 is best</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with knee sleeve at 3 months</measure>
    <time_frame>3 months (T2)</time_frame>
    <description>0-10, 10 is best</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with knee sleeve at 6 months</measure>
    <time_frame>6 months (T3)</time_frame>
    <description>0-10, 10 is best</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average wear time of sleeve over past week at 4 weeks</measure>
    <time_frame>4 weeks (T1)</time_frame>
    <description>0-24 hours, 24 hours is best</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average wear time of sleeve over past week at 3 months</measure>
    <time_frame>3 months (T2)</time_frame>
    <description>0-24 hours, 24 hours is best</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average wear time of sleeve over past week at 6 months</measure>
    <time_frame>6 months (T3)</time_frame>
    <description>0-24 hours, 24 hours is best</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Reparel Sleeve Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reparel sleeve and corticosteroid injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Sleeve Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo sleeve and corticosteroid injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Reparel knee sleeve</intervention_name>
    <description>Unlabelled thermo-active knee sleeve that improves bloodflow to knee and decreased pain</description>
    <arm_group_label>Reparel Sleeve Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid injection</intervention_name>
    <description>intraarticular knee injection of betamethasone and bupivacaine 0.5% (dose is determined by joint size)</description>
    <arm_group_label>Placebo Sleeve Group</arm_group_label>
    <arm_group_label>Reparel Sleeve Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo knee sleeve</intervention_name>
    <description>unlabeled compression knee sleeve</description>
    <arm_group_label>Placebo Sleeve Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  osteoarthritis visible on knee radiograph&#xD;
&#xD;
          -  patient opting for non-surgical treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  bilateral symptomatic knee osteoarthritis&#xD;
&#xD;
          -  prior surgery on the knee of interest&#xD;
&#xD;
          -  hardware present on the knee of interest&#xD;
&#xD;
          -  gross instability detected on physical exam&#xD;
&#xD;
          -  malignancy in the knee of question&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Amit Momaya</investigator_full_name>
    <investigator_title>Assistant Professor, Section Chief, Sports Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

